BioPharmSignal logoBioPharmSignal

Biotech News

Pulmonx Reports First Quarter 2026 Financial Results

Pulmonx (LUNG)PulmonxEarnings

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026.

Related news

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

ANGOAngioDynamics2026-10-08 10:02 EST

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

HYPRHyperfine2026-10-08 11:30 EST

Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026

IARTIntegra LifeSciences2026-10-06 12:30 EST

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

IRIXIRIDEX2026-08-18 20:05 EST

Iridex Reports Second Quarter 2026 Financial Results

FEMYFEMASYS2026-08-14 20:05 EST

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

XAIRBeyond Air2026-08-13 11:00 EST

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

STIMNeuronetics2026-08-11 11:50 EST

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

TMCITreace Medical Concepts2026-08-07 11:05 EST

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

NEPHNephros2026-08-06 20:10 EST

Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026

View all latest news

Pulmonx

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

LUNGPulmonx2026-09-01 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-08-27 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

LUNGPulmonx2026-07-15 20:05 EST

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

Stock data

Close
1.78 USD
Market cap
68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States